Global Insomnia Treatment Drugs Market by Drug (Sedative - Hypnotics, Antidepressants, Antihistamine), by Formulation (Tablet, Capsule), Type of Insomnia (Adjustment Insomnia, Psychophysiological Insomnia, Inadequate Sleep Habit) and By Region – Global Outlook & Forecast 2022-2030
According to the deep-dive market assessment study conducted by Growth+ Reports, The Global Insomnia Treatment Drugs Market was pegged at ~US$ 2.8 billion in 2021. The market is expected to witness a CAGR of ~4.2% from 2022 to 2030.
Insomnia is a sleep disorder that can make it hard to fall asleep, not able to maintain sleep, and unable to resume sleep after sudden weak up which causes serious health problems. According to CDC (Centers for Disease Control and Prevention), adults from age, 18 to 60 need at least 7+ more hours of sleep. Insomnia affects health, body energy level, work performance, mood, and quality time of life. Research has found that insufficient sleep is linked to an increased risk for the development of type 2 diabetes, and cardiovascular diseases notably, hypertension, stroke, coronary heart disease, and irregular heartbeat.
A normal human spends one-third lives sleeping. Sleeping is also basic human need like drinking and eating and it is needed for mental and physical health well being. Sleeping is important for metabolic regulation, hormone stigmatization, and body growth. According, to the Centre For Diseases Control and Prevention, insufficient sleep increased the risk for the development of type 2 diabetes. HbA1c is important marker for predication blood sugar control which depends on sleep duration and quality. Optimizing sleep duration and quality improving blood sugar control in persons with type 2 diabetes. Insufficient sleep increased risk for the development of type 2 diabetes. HbA1c is important marker for predication blood sugar control which depends on sleep duration and quality. Optimizing sleep duration and quality improving blood sugar control in persons with type 2 diabetes.
The global insomnia treatment drugs market is driven by changes in lifestyle, changes in working shifts, depression, changes in sleeping schedule, family history of insomnia, growing geriatric population, and increasing awareness about various treatment options for Insominia. However, overuse of insomnia drugs may cause addiction, dependency. Higher adoption of generic
products available at a cheaper cost negatively affect the growth of the insomnia treatment drugs market. The availability of alternatives for the treatment of insomnia antipsychotics, tricyclic antidepressants, and chloral derivatives are also restraining market growth.
The market has been segmented into adjustment insomnia, behavioral insomnia of childhood, idiopathic insomnia, inadequate sleep hygiene, insomnia due to drug or substance, medical condition, or mental disorder, paradoxical insomnia, and psychophysiological insomnia. At present, adjustment insomnia dominates the insomnia treatment drugs market with the highest share during the forecast period. The growth of the segment can be attributed to the prevalence of sleeping disorder, growing cases of mental health instability, stress, depression, and hypertension. In May 2020, the American sleep foundation released a note that women have more risk of insomnia and have 40% higher chances as compared to men. Around 40% of people who have insomnia are believing to have mental health disorder. The drug classification used for the treatment of insomnia is sedative-hypnotics, antidepressants, antihistamines, and others. The sedative-hypnotics segment is expected to hold the highest share during the forecast period owing to its benefits used for the treatment of various diseases like mental issues, psychotic disorders, sleep disorders, Alzheimer's disease, and so forth. For instance, in June 2020, 3Z pharmaceutical received $ 2 million in funding for the preclinical development of novel insomnia and ADHD therapeutics.
North America leads the insomnia treatment drugs market and driving factor for the growth of this market is rising cases of sleeping disorders in this region, and awareness about the sleeping disorder. In May 2022, US Sleep Foundation stated that an average 35.2% of all adults in U.S. get less than seven hours per night sleep. Insomnia is also caused by prescription drugs, medical disorders, atress, abnormal health conditions and substance abuse. Also, in May 2022, Idorsia launched QUVIVIQ (daridorexant) a new treatment for insomnia, and is now available in the US. Many pharma companies are rigorously launching their products in North America. All these factors are projecting the growth of the insomnia treatment drugs market in the region.
Some of the prominent players operating in the global insomnia treatment drugs market are Heptares Therapeutics (Sosei Group Corporation), Mylan (Viatris Inc.), Takeda Pharmaceutical Company Ltd., Evotec SE, Eisai Co., Ltd, Currax™ Holdings USA LLC, Merck KgaA, Astellas Pharma, Alexza Pharmaceuticals (Ferrer Therapeutics, Inc.) and Zydus Cadila.